Nkarta, Inc.
No enriched coverage for $NKTX in the last 7 days.
No SEC Form 4 filings for $NKTX in the last 30 days.
See all $NKTX insider activity →Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001787400 false 0001787400 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( NASDAQ:NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conferences next month:
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conferences next month: ...
Recent NKTX coverage spans financial news and corporate actions.
The filing is a corporate governance update (board/director and say-on-pay mechanics) with no new operating or financial guidance.
Nkarta's participation in upcoming investor conferences may positively influence investor interest and stock liquidity, but the event's impact on stock price is likely limited unless accompanied by material updates.
Nkarta's participation in upcoming investor conferences signals ongoing efforts to attract investment and showcase pipeline progress. The news has a neutral to slightly positive impact on NKTX, as it indicates active investor engagement but lacks immediate financial data or clinical updates.
The announcement of a poster presentation at the ACR Convergence Meeting indicates active research and development efforts, potentially signaling ongoing progress in Nkarta's pipeline. This could positively influence investor sentiment and stock performance in the short to medium term.
Nkarta announced a poster presentation at the upcoming ACR Convergence Meeting, indicating ongoing research and potential advancements in its therapeutic pipeline.
alphai scores every news story that mentions NKTX with an AI model for sentiment and relevance, and aggregates insider trades from Nkarta, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001787400 false 0001787400 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
2 min readSOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( NASDAQ:NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conferences next month:
2 min readSOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conferences next month: ...
2 min readSOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( NASDAQ:NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago ...
3 min readSOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in ...
2 min readSOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the following investor conference: ...
1 min readNkarta ( NASDAQ:NKTX ) , a clinical-stage biotechnology company specializing in allogeneic NK cell therapies for autoimmune diseases, reported its second-quarter earnings on August 12, 2025, covering results for the period ended June 30, 2025.
3 min readSOUTH SAN FRANCISCO, Calif., July 23, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies, today announced its participation in the H.C. Wainwright "HCW@Home" Series.
2 min readSOUTH SAN FRANCISCO, Calif., June 06, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D.
2 min readNkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 min read
